Contact
Please use this form to send email to PR contact of this press release:
FDA Orphan Drug Approval: Octapharma’s Octagam® 10% Receives 7 Years of Market Exclusivity for Adult Dermatomyositis
TO:
Please use this form to send email to PR contact of this press release:
FDA Orphan Drug Approval: Octapharma’s Octagam® 10% Receives 7 Years of Market Exclusivity for Adult Dermatomyositis
TO: